<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00839540</url>
  </required_header>
  <id_info>
    <org_study_id>PA-07-004</org_study_id>
    <nct_id>NCT00839540</nct_id>
  </id_info>
  <brief_title>Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins</brief_title>
  <official_title>Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins in Patients With Presumptive Candidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gary E. Stein, Pharm.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Michigan State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pharmacokinetic (PK) and pharmacodynamic (PD) study is:

      To study the rate and duration of serum cidal activity of caspofungin (CFG) and micafungin
      (MFG) against Candida isolates from the subject and against Candida glabrata with varying
      degrees of caspofungin susceptibilities.

      This investigation will provide clinicians information supporting the use of caspofungin and
      micafungin in situations where Candida strains may be a cause of infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods:

      Patients - Adult patients with presumptive candidemia. Patients with severe neutropenia
      (&lt;500) APACHE II scores &gt; 20, or significant liver disease will be excluded. All will give
      written informed consent (Pappas et al. CID. Oct 1, 2007).

      Drugs - Patients will receive either CFG: 70 mg loading dose (LD) followed by 50 mg once
      daily (qd) (8 patients), MFG: 100 mg qd (8 patients) or MFG: 200 mg qd (8 patients). All
      agents will be given by slow IV infusion (MFG will be supplied by Astellas).

      Sera - Blood samples will be collected at the end of the infusion (peak) and at 12 h and 24 h
      (trough) after the beginning of an infusion (day 3-4).

      Each patients sera will be tested (MIC and cidal activity) against their own Candida isolate
      (if isolated). In addition, recent clinical isolates of C. glabrata will also be tested
      against patient sera (time-kill) to verify previous in vitro and animal PD studies (Cota.
      AAC. Nov. 2006; Wiederhold. AAC. May 2007).

      Results:

        -  Patient outcome, including Candida eradication, will be documented for each patient by
           repeat culture.

        -  Serum concentrations (lab to be determined) and PK analysis of each echinocandin will be
           determined for each patient.

        -  Serum cidal titers will be measured against each of the Candida isolates for each agent
           at each time period. Median and geometric mean Peak and duration of cidal activity will
           then be determined and compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Cidal Activity as Tested Against Various Candida Isolates and Reported as Ex-vivo Effect (Log Inhibition of Growth)</measure>
    <time_frame>Pre-treatment, 1.5 hour (h), 12 h and 24 h after receiving the drug</time_frame>
    <description>Serum cidal activity of serum collected at different timepoints from the patients will be tested against various Candida isolates and the ex-vivo effect reported as log inhibition (logrithmic measurement of the decrease in microbiological growth).
These Candida isolates had a range of minimum inhibitory concentrations (MIC) to Caspofungin (C) and Micafungin (M).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Candidemia</condition>
  <arm_group>
    <arm_group_label>micafungin 100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive Micafungin 100 mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>micafungin 200</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive 200 mg Micafungin qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caspofungin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive caspofungin 70 mg LD followed by 50 mg qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>micafungin</intervention_name>
    <description>100 mg qd by slow IV infusion for 24 h</description>
    <arm_group_label>micafungin 100</arm_group_label>
    <other_name>Micamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micafungin</intervention_name>
    <description>200 mg qd by slow IV infusion for 24 h</description>
    <arm_group_label>micafungin 200</arm_group_label>
    <other_name>Micamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caspofungin</intervention_name>
    <description>70 mg LD followed by 50 mg qd by slow IV infusion for 24 h</description>
    <arm_group_label>Caspofungin</arm_group_label>
    <other_name>Cancidas</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with presumptive candidemia

        Exclusion Criteria:

          -  Patients with severe neutropenia (&lt;500)

          -  Patients with APACHE II scores &gt; 20

          -  Patients with severe liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary E Stein, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sparrow Hospital</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>February 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2009</study_first_posted>
  <results_first_submitted>January 23, 2012</results_first_submitted>
  <results_first_submitted_qc>January 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 24, 2012</results_first_posted>
  <last_update_submitted>February 27, 2012</last_update_submitted>
  <last_update_submitted_qc>February 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Michigan State University</investigator_affiliation>
    <investigator_full_name>Gary E. Stein, Pharm.D.</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>candidemia</keyword>
  <keyword>echinocandin</keyword>
  <keyword>micafungin</keyword>
  <keyword>caspofungin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Micafungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
    <mesh_term>Caspofungin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were inpatients (Sparrow Hospital) with probable fungal infections that required treatment with an antifungal; referral base was infectious disease consultations. The first subject was enrolled 12/24/08, with the last subject enrolled on 1/15/10.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Micafungin (M) 100</title>
          <description>Patients receive Micafungin (M) 100 mg once daily (qd)</description>
        </group>
        <group group_id="P2">
          <title>Micafungin (M) 200</title>
          <description>Patients receive 200 mg Micafungin (M) once daily</description>
        </group>
        <group group_id="P3">
          <title>Caspofungin (C) 50</title>
          <description>Patients receive caspofungin 70 mg loading dose (LD) followed by 50 mg once daily (qd)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Micafungin (M) 100</title>
          <description>Patients receive Micafungin (M) 100 mg once daily (qd)</description>
        </group>
        <group group_id="B2">
          <title>Micafungin (M) 200</title>
          <description>Patients receive 200 mg Micafungin (M) once daily</description>
        </group>
        <group group_id="B3">
          <title>Caspofungin (C) 50</title>
          <description>Patients receive caspofungin 70 mg loading dose (LD) followed by 50 mg once daily (qd)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.62" spread="16.13282"/>
                    <measurement group_id="B2" value="57.81" spread="17.38585"/>
                    <measurement group_id="B3" value="44.0" spread="20.43282"/>
                    <measurement group_id="B4" value="57.6" spread="18.65374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Cidal Activity as Tested Against Various Candida Isolates and Reported as Ex-vivo Effect (Log Inhibition of Growth)</title>
        <description>Serum cidal activity of serum collected at different timepoints from the patients will be tested against various Candida isolates and the ex-vivo effect reported as log inhibition (logrithmic measurement of the decrease in microbiological growth).
These Candida isolates had a range of minimum inhibitory concentrations (MIC) to Caspofungin (C) and Micafungin (M).</description>
        <time_frame>Pre-treatment, 1.5 hour (h), 12 h and 24 h after receiving the drug</time_frame>
        <population>Each subject received drug and had serum samples drawn at pre-treatment, 1.5h, 12h, and 24h after dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Log Inhibition of 50 mg/Day Caspofungin on Candida Spp.</title>
            <description>Measurement of the decrease in organism(Candida spp.) colony counts following exposure of serum containing Caspofungin based on 50 mg/day dosing, measured as Ex-vivo effect.</description>
          </group>
          <group group_id="O2">
            <title>Log Inhibition of 100 mg/Day Micafungin on Candida Spp.</title>
            <description>Measurement of the decrease in organism(Candida spp.) colony counts following exposure of serum containing Micafungin based on 100 mg/day dosing, measured as Ex-vivo effect.</description>
          </group>
          <group group_id="O3">
            <title>Log Inhibition of 200 mg/Day Micafungin on Candida Spp.</title>
            <description>Measurement of the decrease in organism(Candida spp.) colony counts following exposure of serum containing Micafungin based on 200 mg/day dosing, measured as Ex-vivo effect.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Cidal Activity as Tested Against Various Candida Isolates and Reported as Ex-vivo Effect (Log Inhibition of Growth)</title>
          <description>Serum cidal activity of serum collected at different timepoints from the patients will be tested against various Candida isolates and the ex-vivo effect reported as log inhibition (logrithmic measurement of the decrease in microbiological growth).
These Candida isolates had a range of minimum inhibitory concentrations (MIC) to Caspofungin (C) and Micafungin (M).</description>
          <population>Each subject received drug and had serum samples drawn at pre-treatment, 1.5h, 12h, and 24h after dosing.</population>
          <units>Log inhibition</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>blood samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C. albicans MIC: C, M 0.016 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C. glabrata MIC: C, M 0.06 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1.5"/>
                    <measurement group_id="O3" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C. glabrata MIC: C, M 0.25 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C. albicans 119 FKS mutant MIC:C 1, M 0.16 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C. albicans 90 FKS mutant MIC: C 1, M 0.25 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C. albicans A-15 FKS mutant MIC: C 2, M0.5 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C. glabrata MIC: C 2, M 0.5 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C. albicans 117 FKS mutant MIC: C 8, M 0.83 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Micafungin (M) 100</title>
          <description>Patients receive Micafungin (M) 100 mg once daily (qd)</description>
        </group>
        <group group_id="E2">
          <title>Micafungin (M) 200</title>
          <description>Patients receive 200 mg Micafungin (M) once daily</description>
        </group>
        <group group_id="E3">
          <title>Caspofungin (C) 50</title>
          <description>Patients receive caspofungin 70 mg loading dose (LD) followed by 50 mg once daily (qd)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Death due to disease progression (fungal infection), not related to study participation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gary E.Stein, Pharm.D.</name_or_title>
      <organization>Michigan State University</organization>
      <phone>517-353-5126</phone>
      <email>steing@msu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

